Semaglutide — a GLP‑1 receptor agonist used to help regulate metabolism — is now a mainstay of medically supervised weight loss. A new cash-pay pathway brings that therapy within reach for many Dallas patients.
The recent federal drug‑price negotiation initiative launched under the Trump administration creates a new pathway to lower out‑of‑pocket costs for high‑price therapies — including GLP‑1 weight‑loss medications — for people living in metro areas like Dallas.
Dallas is seeing a surge in interest in GLP‑1 weight-loss therapies. Alongside legitimate offerings, a dangerous trend has emerged: compounded, unapproved versions of Semaglutide and Tirzepatide marketed at bargain prices.
Republic Center
325 N. St. Paul Street, Suite 3100
Dallas, TX 75201
